非酒精性脂肪性肝病相关慢性肾病研究进展

doi:10.3969/j.issn.1672-5069.2016.03.033

摘要/Abstract

摘要： 非酒精性脂肪性肝病是与胰岛素抵抗和遗传易感性密切相关的代谢应激性肝损伤。该病已经成为全球性的公共卫生问题之一。近几年来，有研究显示非酒精性脂肪性肝病可能与慢性肾病越来越高的患病率有关。本文将重点阐述这两个疾病的相互关系以及相关发生机制，比如胰岛素抵抗、炎症、氧化应激、高凝状态、胎球蛋白-A和脂联素等在该病发病中的作用，为更全面管理非酒精性脂肪性肝病患者和慢性肾病患者提供有用的建议。

关键词: 非酒精性脂肪性肝病, 慢性肾病, 代谢综合征, 胰岛素抵抗

Abstract: Non-alcoholic fatty liver diseases （NAFLD） is an acquired metabolic stress-induced liver diseases associated with insulin resistance and genetic susceptibility，which has become one of the global public health problems. Accumulating evidence suggests that NAFLD may be associated with an increased prevalence and incidence of chronic kidney disease （CKD）. In this review，the evidence of NAFLD related to CKD，and the putative mechanisms by which nonalcoholic fatty liver disease contributes to kidney damage will be reviewed，and we hope it will provide guidance and recommendations for more comprehensive management of patients with nonalcoholic fatty liver disease or chronic kidney disease.

Key words: Nonalcoholic fatty liver disease, Chronic kidney disease, Metabolic syndrome, Insulin resistance

雷婷，李良平. 非酒精性脂肪性肝病相关慢性肾病研究进展[J]. 实用肝脏病杂志, 2016, 19(3): 373-376.

Lei Ting,Li Liangping. Chronic kidney disease in patients with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 373-376.

参考文献

[1] Review T，LaBrecque DR，Abbas Z，et al. World gastroenterology organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholicsteatohepatitis. J Clin Gastroenterol，2014，48（6）:467-473.
[2] James MT，Hemmelgarn BR，Tonelli M. Early recognition and prevention of chronic kidney disease.Lancet，2010，375（9722）:1296-1309.
[3] Younossi ZM，Stepanova M，Afendy M，et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol，2011，9（6）:524-530.
[4] Welsh JA，Karpen S，Vos MB.Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents，1988-1994 to 2007-2010. J Pediatr，2013，162（3）:496-500.
[5] Okanoue T，Umemura A，Yasui K，et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan.J Gastroenterol Hepatol，2011，26（1）:153-162.
[6] 梁国威，徐旭，刘耘，等. 北京地区成年人血尿酸和非酒精性脂肪肝相关性研究. 医学研究杂志，2011，40（12）：66-69.
[7] 秦恳，周婷，吴琴琴，等. 成都地区非酒精性脂肪肝与代谢综合征相关性研究. 现代预防医学，2012，39（10）：2395-2397.
[8] 李萍，傅晓英，许谷根. 广州地区健康体检人群非酒精性脂肪肝与代谢综合征的发病情况分析. 当代医学，2012，18（5）：162-163.
[9] 陆喜燕，董国庆，钟丽华，等. 单纯性肥胖患儿非酒精性脂肪性肝病与胰岛素抵抗. 实用儿科临床杂志，2012，27（11）：859-861.
[10] Stauffer ME，Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One，2014，9（1）:e84943.
[11] Mallett A，Patel C，Salisbury A，et al. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis，2014，9:98.
[12] Zhang L，Wang F，Wang L，et al. Prevalence of chronic kidney disease in China:a cross-sectional survey. Lancet，2012，379（9818）:815-822.
[13] Coresh J，Astor BC，Greene T，et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey. Am J Kidney Dis，2003，41（1）:1-12.
[14] Johns BR，Pao AC，Kim SH. Metabolic syndrome，insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant，2012，27（4）:1410-1415.
[15] Ferraro PM，Lupo A，Yabarek T，et al. Metabolic syndrome，cardiovascular disease，and risk for chronic kidney disease in an Italian cohort:analysis of the INCIPE study. Metab Syndr Relat Disord，2011，9（5）:381-388.
[16] Thomas G，Sehgal AR， Kashyap SR，et al. Metabolic syndrome and kidney disease:a systematic review and meta-analysis. Clin J Am Soc Nephrol，2011，6（10）:2364-2373.
[17] Schuppan D，Schattenberg JM. Non-alcoholic steatohepatitis:pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol，2013（Suppl 1）:68-76.
[18] Pham H，Robinson-Cohen C，Biggs ML，et al. Chronic kidney disease，insulin resistance，and incident diabetes in older adults.Clin J Am Soc Nephrol，2012，7（4）:588-594.
[19] Targher G，Chonchol M，Zoppini G，et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease:is there a link J Hepatol，2011，54（5）:1020-1029.
[20] Guleria A，Duseja A，Kalra N，et al. Patients with non-alcoholic fatty liver disease（NAFLD） have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol，2013，34（2）:74-82.
[21] Targher G，Bertolini L，Chonchol M，et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.Diabetologia.2010，53（7）:1341-1348.
[22] Hwang ST，Cho YK，Yun JW，et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J，2010，40（6）:437-442.
[23] Targher G，Pichiri I，Zoppini G，et al. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med，2012，29（2）:220-226.
[24] Targher G，Bertolini L，Rodella S，et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol，2010，5（12）:2166-2171.
[25] Yilmaz Y，Alahdab YO，Yonal O，et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease:association with liver fibrosis. Metabolism，2010，59（9）:1327-1330.
[26] Yasui K，Sumida Y，Mori Y，et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease.Metabolism，2011，60（5）:735-739.
[27] Machado MV， Goncalves S，Carepa F，et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int，2012，32（2）:241-248.
[28] Byrne CD.Dorothy Hodgkin Lecture 2012:non-alcoholic fatty liver disease，insulin resistance and ectopic fat:a new problem in diabetes management.Diabet Med，2012，29（9）:1098-1107.
[29] Sabio G，Davis RJ. cJun NH2-terminal kinase 1（JNK1）:roles in metabolic regulation of insulin resistance. Trends Biochem Sci，2010，35（9）:490-496.
[30] Sharma M，Mitnala S，Vishnubhotla RK，et al. The riddle of nonalcoholic fatty liver disease:Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol，2015，5（2）:147-158.
[31] Tilg H，Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology，2010，52（5）:1836-1846.
[32] Vaziri ND，Liu SM，Lau WL，et al. High amylase resistant starch diet ameliorates oxidative stress，inflammation，and progression of chronic kidney disease. PLoS One，2014，9（12）:e114881.
[33] Ix JH，Sharma K.Mechanisms linking obesity，chronic kidney disease，and fatty liver disease:the roles of fetuin-A，adiponectin，and AMPK. J Am Soc Nephrol，2010，21（3）:406-412.
[34] Kadowaki T，Yamauchi T，Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS.FEBS Lett，2008，582（1）:74-80.
[35] Sharma K，Ramachandrarao S，Qiu G，et al. Adiponectin regulates albuminuria and podocyte function in mice.J Clin Invest，2008，118（5）:1645-1656.
[36] Declèves AE，Mathew AV，Cunard R，et al. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol，2011，22（10）:1846-1855.
[37] Gurkan C，Halil G，Hasan G，et al. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.Saudi J Gastroenterol，2015，21（3）:139-145.